Compound 2f (SARM) is a drug which acts as a
selective androgen receptor modulator (SARM), originally developed by
Takeda Pharmaceutical for the treatment of
prostate cancer. It is a potent but tissue specific androgen agonist with an EC50 of 4.7nM, producing
anabolic effects on muscles and in the central nervous system but with little effect on the prostate gland, and inducing sexual behaviour in animal studies.[1][2][3]
^US 8420694, Hasuoka A, "Pyrrolidin-2-one derivatives as androgen receptor modulator", issued 16 April 2013, assigned to Takeda Pharmaceutical Co Ltd.
^Aikawa K, Asano M, Ono K, Habuka N, Yano J, Wilson K, et al. (July 2017). "Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate". Bioorganic & Medicinal Chemistry. 25 (13): 3330–3349.
doi:
10.1016/j.bmc.2017.04.018.
PMID28454849.